As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

• 

• Jeffrey I. Weitz, MD, FRACP

  Professor of Medicine and Biochemistry, McMaster University; Executive Director, Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada

  Disclosures

  Disclosure: Jeffrey I. Weitz, MD, FRCPC, has disclosed the following relevant financial information:
  Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Isis Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc; Portola Pharmaceuticals, Inc.
  
  Dr Weitz does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
  
  Dr Weitz does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

• 

• Alex C. Spyropoulos, MD

  Director, Anticoagulation and Clinical Thrombosis Services, North Shore-LIJ Health System; Professor of Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, United States

  Disclosures

  Disclosure: Alex C. Spyropoulos, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Pfizer Inc.
  
  Dr Spyropoulos does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
  
  Dr Spyropoulos does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

• 

• Mark A. Crowther, MD, MSc

  Professor, Pathology and Molecular Medicine, Medicine and Clinical Epidemiology and Biostatistics; Chair, Department of Pathology and Molecular Medicine; Leo Pharma Chair in Thromboembolism Research, McMaster University, Hamilton, Ontario, Canada

  Disclosures

  Disclosure: Mark A. Crowther, MD, FRCPC, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Octapharma; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer Inc.; Portola Pharmaceuticals, Inc.
  Received grants for clinical research from: Bayer AG; Heart and Stroke Foundation of Canada; LEO Pharma Inc.
  
  Dr Crowther, does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
  
  Dr Crowther, does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

• 

• Jan Beyer-Westendorf, MD

  Professor, Head of Thrombosis Research, Center for Vascular Diseases, University Hospital Carl Gustav Carus, Dresden, Germany

  Disclosures

  Disclosure: Jan Beyer-Westendorf, PD, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Pfizer Inc
  Served as a speaker or a member of a speakers' bureau for: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc.; Pfizer Inc
  Received grants for clinical research from: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc.;Daiichi Sankyo, Inc.; Pfizer Inc
  
  Jan Beyer-Westendorf, MD, does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
  
  Jan Beyer-Westendorf, MD, does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

• 

• Rupert M. Bauersachs, MD

  Professor and Doctor, Vascular Medicine, Klinikum Damstadt GmbH, Darmstadt, Germany

  Disclosures

  Disclosure: Rupert M. Bauersachs, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc
  Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc
  Received grants for clinical research from: Bayer HealthCare Pharmaceuticals; Pfizer Inc
  
  Dr Bauersachs does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
  
  Dr Bauersachs does not intend to discuss investigational uses of drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

• 

• Philip S. Wells, MD, MSc, FRCPC

  Professor, Chief, and Chair, Department of Medicine, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada

  Disclosures

  Disclosure: Philip S. Wells, MD, MSc, FRCPC, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals
  Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals
  Received grants for clinical research from: Bristol-Myers Squibb Company; Pfizer Inc
  
  Dr Wells does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
  
  Dr Wells does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

• Keith A. A. Fox, MB, ChB

  Professor of Cardiology, Centre for Cardiovascular Science; University of Edinburgh, Edinburgh, United Kingdom

  Disclosures

  Disclosure: Keith A. A. Fox, MB, ChB, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Lilly; Sanofi
  Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Janssen Pharmaceuticals, Inc.
  Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Lilly

• Dan Atar, MD

  Professor and Head, Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway

  Disclosures

  Disclosure: Dan Atar, MD, has disclosed the following relevant financial relationships: Dan Atar, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Cardiome Pharma Corp.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Nycomed; Pfizer Inc; Sanofi; Takeda Pharmaceuticals North America, Inc.

• Lord Ajay K. Kakkar, MD, PhD

  Director, Thrombosis Research Institute; Professor of Surgery, University College London, London, United Kingdom

  Disclosures

  Disclosure: Lord Ajay K. Kakkar, MD, PhD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Sanofi
  Received grants for clinical research from: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.

• Jessica L. Mega, MD, MPH

  Cardiologist, Brigham and Women's Hospital; Investigator, TIMI Study Group; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

  Disclosures

  Disclosure: Jessica L. Mega, MD, MPH, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: American Genomics; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.
  Received grants for clinical research from: Accumetrics, Inc.; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lilly; Nanosphere, Inc.; Sanofi

• P. Gabriel Steg, MD

  Professor, Department of Cardiology; Director, Coronary Care Unit, Hôpital Bichat-Claude Bernard, Service de Cardiologie; Faculté de Médecine Xavier Bichat, Université de Paris XII, Paris, France

  Disclosures

  Disclosure: P. Gabriel Steg, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Amarin Corporation plc; AstraZeneca Pharmaceuticals LP; Bayer Healthcare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd; Pfizer Inc; Regado Biosciences; Roche; Sanofi; SERVIER; The Medicines Company; VIVUS Inc.
  Received grants for clinical research from: Sanofi; SERVIER
  Owns stock, stock options, or bonds from: Aterovax

• Alexander G. G. Turpie, MD

  Professor of Medicine, McMaster University, Hamilton, Ontario, Canada

  Disclosures

  Disclosure: Alexander G. G. Turpie, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.
  Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc

Editor

• Caroline M. Padbury, B.Pharm

  Lead Scientific Director, Medscape LLC

  Disclosures

  Disclosure: Caroline M. Padbury, B.Pharm, has disclosed no relevant financial relationships.

CME Reviewer

• Amy Bernard, MS, BSN, RN-BC

  Lead Nurse Planner, Medscape, LLC

  Disclosures

  Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

Received grants for clinical research from: Otsuka Pharmaceutical Co., Ltd.
Served as an advisor or consultant for: HeartWare International, Inc.; Thoratec Corporation